Return to Statistics Toolbox

Volcano Plot analysis for Study ST001237

(Analysis All analyses used)
Select one or more experimental factors for Groups 1 and 2. The members of each group should be DIFFERENT.
Group1Experimental factorGroup2
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (39)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (14)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (45)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (13)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (41)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (6)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (47)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (11)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (5)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (1)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (12)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (51)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (19)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (57)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (19)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (92)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (24)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (95)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (29)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (39)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (18)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (47)
Time point:baseline | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (15)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (9)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (21)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (6)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (13)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (5)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (1)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (10)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (1)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (10)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (5)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (16)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (20)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (7)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):FALSE (3)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:EVEROLIMUS | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (8)
Time point:week 4 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (44)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (12)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (41)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (10)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (12)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):1 | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (2)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (42)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:FAVORABLE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (15)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (74)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:INTERMEDIATE | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (24)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):FALSE (38)
Time point:week 8 | OS_Censor (1 means the time is a censoring time and 0 means a failure time in OS):- | CRF_MSKCC_Risk_Group:POOR | Treatment:NIVOLUMAB | Prior antiangiogenic regimens (≥2):TRUE (10)
P-value cutoff:    Fold-change cutoff:    Sample normalization:
Group by metabolite classification:    Use:
Maximum # of (most significant) metabolites per class to use in pvalue group calculation:
Analysis:Combine data for all analyses?:     

  logo